Nagel J

References (4)

Title : IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease - Winblad_2007_Neurology_69_S14
Author(s) : Winblad B , Grossberg G , Frolich L , Farlow M , Zechner S , Nagel J , Lane R
Ref : Neurology , 69 :S14 , 2007
Abstract : Winblad_2007_Neurology_69_S14
ESTHER : Winblad_2007_Neurology_69_S14
PubMedSearch : Winblad_2007_Neurology_69_S14
PubMedID: 17646619

Title : Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease - Blesa_2006_Pharmacogenet.Genomics_16_771
Author(s) : Blesa R , Bullock R , He Y , Bergman H , Gambina G , Meyer J , Rapatz G , Nagel J , Lane R
Ref : Pharmacogenet Genomics , 16 :771 , 2006
Abstract : Blesa_2006_Pharmacogenet.Genomics_16_771
ESTHER : Blesa_2006_Pharmacogenet.Genomics_16_771
PubMedSearch : Blesa_2006_Pharmacogenet.Genomics_16_771
PubMedID: 17047484

Title : Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease - Bullock_2006_Curr.Med.Res.Opin_22_483
Author(s) : Bullock R , Bergman H , Touchon J , Gambina G , He Y , Nagel J , Lane R
Ref : Curr Med Res Opin , 22 :483 , 2006
Abstract : Bullock_2006_Curr.Med.Res.Opin_22_483
ESTHER : Bullock_2006_Curr.Med.Res.Opin_22_483
PubMedSearch : Bullock_2006_Curr.Med.Res.Opin_22_483
PubMedID: 16574032

Title : Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period - Bullock_2005_Curr.Med.Res.Opin_21_1317
Author(s) : Bullock R , Touchon J , Bergman H , Gambina G , He Y , Rapatz G , Nagel J , Lane R
Ref : Curr Med Res Opin , 21 :1317 , 2005
Abstract : Bullock_2005_Curr.Med.Res.Opin_21_1317
ESTHER : Bullock_2005_Curr.Med.Res.Opin_21_1317
PubMedSearch : Bullock_2005_Curr.Med.Res.Opin_21_1317
PubMedID: 16083542